Caribou Biosciences Announces Dosing of First Patient in the CaMMouflage Phase 1 Trial of CB-011, an Allogeneic Anti-BCMA CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Multiple Myeloma
29 mars 2023 08h00 HE
|
Caribou Biosciences, Inc.
-- CB-011 is designed to improve antitumor activity by cloaking the allogeneic CAR-T cells from immune-mediated rejection -- -- CB-011 is Caribou’s second program to enter the clinic from its...
iOmx Therapeutics to Present Target Discovery Platform Myeloid iOTarg™ and New Data on SIK Checkpoint Inhibitor OMX-0407 at AACR 2023
15 mars 2023 10h30 HE
|
iOmx Therapeutics AG
Discovery of novel immune checkpoints in the tumor microenvironment with iOTarg™ screening platformPredictive biomarker signature for lead product candidate OMX-0407 MUNICH, Germany, March 15, 2023 ...
Caribou Biosciences Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
09 mars 2023 17h09 HE
|
Caribou Biosciences, Inc.
-- CB-010 ANTLER Phase 1 trial in r/r B-NHL ongoing with update planned for H2 2023 -- -- CB-011 CaMMouflage Phase 1 trial in r/r MM recruiting patients at dose level 1 -- -- CB-012 IND-enabling...
India Gene Editing Technology Market Databook Report 2023-2027: CRISPR, Meganucleases, TALEN, and ZFN Products, Delivery Method, Disease/Disorders, and Applications
03 mars 2023 06h58 HE
|
Research and Markets
Dublin, March 03, 2023 (GLOBE NEWSWIRE) -- The "India Gene Editing Technology Business and Investment Opportunities Databook - Q1 2023 Update" report has been added to ResearchAndMarkets.com's...
Intellia Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application for NTLA-2002, an In Vivo CRISPR-Based Investigational Therapy for the Treatment of Hereditary Angioedema (HAE)
02 mars 2023 07h00 HE
|
Intellia Therapeutics, Inc.
CAMBRIDGE, Mass., March 02, 2023 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapies...
China Gene Editing Technology Market Databook Report 2023: Business and Investment Opportunities to 2027
27 févr. 2023 10h33 HE
|
Research and Markets
Dublin, Feb. 27, 2023 (GLOBE NEWSWIRE) -- The "China Gene Editing Technology Business and Investment Opportunities Databook - Q1 2023 Update" report has been added to ResearchAndMarkets.com's...
Advances in Gene Editing Technologies in Healthcare, 2023 Research Report - Next-Generation Genome Editing Tools and Improved Delivery Are Bolstering Gene Editing Therapeutics and Diagnostics
10 févr. 2023 10h53 HE
|
Research and Markets
Dublin, Feb. 10, 2023 (GLOBE NEWSWIRE) -- The "Advances in Gene Editing Technologies in Healthcare" report has been added to ResearchAndMarkets.com's offering. CRISPR, ZFNs, and TALENs are...
Global CRISPR Gene Detection and Diagnostic Market Report 2023: Simultaneous Detection of Multiple Gene Targets Opens Up Huge Market Opportunities That Go Beyond Clinical Use
08 févr. 2023 04h23 HE
|
Research and Markets
Dublin, Feb. 08, 2023 (GLOBE NEWSWIRE) -- The "CRISPR Gene Detection and Diagnostic Markets by Research, Clinical Lab, Consumer, Public Service & Other with Executive and Consultant Guides. 2023...
Caribou Biosciences to Participate in Upcoming Investor Conferences
01 févr. 2023 16h05 HE
|
Caribou Biosciences, Inc.
BERKELEY, Calif., Feb. 01, 2023 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced Rachel...
CRISPR Technology Global Markets Report 2023: A $9.2 Billion Market by 2027, from $3.3 Billion in 2022
25 janv. 2023 04h08 HE
|
Research and Markets
Dublin, Jan. 25, 2023 (GLOBE NEWSWIRE) -- The "CRISPR Technology: Global Markets" report has been added to ResearchAndMarkets.com's offering. The current report provides detailed exposure to the...